{
  "id": 9196719,
  "title": "Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems",
  "url": "https://urgent.news/2026/09/22/novo-nordisk-has-a-fresh-new-name-but-it-still-faces-the-same-old-9196719",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-22T20:35:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/novo-nordisk-has-fresh-new-name-it-still-faces-same-old-problems"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsNovo Nordisk is in the middle of an important product launch, as it rolls out a pill version of its GLP-1 drug.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems",
        "url": "https://urgent.news/2026/09/22/novo-nordisk-has-a-fresh-new-name-but-it-still-faces-the-same-old",
        "published": "2026-09-22T20:15:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}